Abstract
Background Melanoma is an immunogenic cancer that overcomes the immune surveillance through the production of tolerogenic cytokines and growth factors within microenvironment. Melanoma-derived dendritic cells (DCs) show altered maturation, cross-priming and antigenic presentation and their major defect concerns the activation of the STAT pathway. The prognostic criteria to define melanoma at high-risk of relapse/recurrence include the Breslow depth, the Clark level and number of mitosis. Sentinel lymph node (SLN) characterization is a prognostic factor in melanoma, although false negative occurs in approximately 5% of patients. We investigated the potential prognostic role of DC number variation in relation to clinical stage, and suggest their role as early predictor of high risk melanomas.
Highlights
Melanoma is an immunogenic cancer that overcomes the immune surveillance through the production of tolerogenic cytokines and growth factors within microenvironment
Sentinel lymph node (SLN) characterization is a prognostic factor in melanoma, false negative occurs in approximately 5% of patients
We investigated the potential prognostic role of dendritic cells (DCs) number variation in relation to clinical stage, and suggest their role as early predictor of high risk melanomas
Summary
Circulating dendritic cell levels identify high-risk stage II-III melanoma patients: a potential role as additional prognostic marker. Stefania Stucci1*, Marco Tucci, Anna Passarelli, Francesco Mannavola, Claudia Felici, Giuseppe Giudice, Franco Silvestris
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
